Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q2 2021
Institutional positions in Definium Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 156
- +148 vs. Q1 2021
- Shares held
- 37.8M
- +37.5M (+12,753.2%) vs. Q1 2021
- Total value
- $131.0M
- +$130.1M (+13,959.7%) vs. Q1 2021
- New holders
- 149
- 2 more added
- Sold out
- 1
- 0 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DFTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 362 | $5.35B |
| Q1 2026 | 248 | $1.47B |
| Q4 2025 | 209 | $908.7M |
| Q3 2025 | 196 | $468.6M |
| Q2 2025 | 183 | $271.0M |
| Q1 2025 | 191 | $240.5M |
| Q4 2024 | 174 | $288.9M |
| Q3 2024 | 158 | $281.6M |
| Q2 2024 | 152 | $299.3M |
| Q1 2024 | 135 | $327.2M |
| Q4 2023 | 104 | $17.9M |
| Q3 2023 | 93 | $12.1M |
| Q2 2023 | 84 | $13.9M |
| Q1 2023 | 89 | $12.6M |
| Q4 2022 | 104 | $11.1M |
| Q3 2022 | 101 | $20.5M |
| Q2 2022 | 156 | $15.1M |
| Q1 2022 | 159 | $53.6M |
| Q4 2021 | 176 | $72.0M |
| Q3 2021 | 175 | $104.8M |
| Q2 2021 | 156 | $131.0M |
| Q1 2021 | 8 | $932.0K |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Definium Therapeutics, Inc.; share changes are against Q1 2021.